Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-05T19:23:21.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    35 days ago
    Change Detected
    Summary
    The page now includes an additional condition keyword 'Fallopian tube cancer' and a new resource link to the Genetic and Rare Diseases Information Center. The page revision is updated from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-12T02:25:20.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page shows a revision from v3.4.0 to v3.4.1, indicating a backend/template update. No study data, eligibility criteria, or results are altered, and To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:38:48.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The changes are minor UI/metadata updates including the addition of a glossary display and revised footer/version information (e.g., Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T19:26:16.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now displayed, replacing the previous v3.3.3. No study data, eligibility criteria, or key content appears to be altered.
    Difference
    0.1%
    Check dated 2026-01-14T03:53:50.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    A centralized 'Locations' section was added, listing Massachusetts and New York sites, consolidating the previous state-specific location headings. The separate 'Massachusetts Locations' and 'New York Locations' subsections were removed, and the HHS Vulnerability Disclosure link was deleted.
    Difference
    0.3%
    Check dated 2025-12-23T21:07:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.